SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ambalal Sarabhai Enterprises touches roof on getting nod to enter into SPA with Asence Pharma

27 Nov 2020 Evaluate

Ambalal Sarabhai Enterprises is currently trading at its upper circuit limit of Rs. 21.15, up by 1.00 points or 4.96% from its previous closing of Rs. 20.15 on the BSE.

The scrip opened at Rs. 21.15 and has touched a high and low of Rs. 21.15 and Rs. 20.65 respectively. So far 84582 shares were traded on the counter.

The BSE group 'X' stock of face value Rs. 10 has touched a 52 week high of Rs. 30.95 on 20-Aug-2020 and a 52 week low of Rs. 10.01 on 02-Dec-2019.

Last one week high and low of the scrip stood at Rs. 21.15 and Rs. 18.85 respectively. The current market cap of the company is Rs. 162.08 crore.

The promoters holding in the company stood at 30.76%, while Institutions and Non-Institutions held 0.01% and 69.24% respectively.

Ambalal Sarabhai Enterprises has received approval to enter into Share Purchase Agreement (SPA) with Asence Pharma for sale of 120446 (35,000 equity shares of face value of Rs 1000 each Rs 100 paid up, and 85,446 equity shares of face value of Rs 1000 each Rs 1000 paid up aggregating 120,446 equity shares) equity shares of Synbiotics, a wholly owned subsidiary to Asence Pharma, another subsidiary of the Company on consideration of Rs 11,91,87,640.

Ambalal Sarabhai Enterprises is engaged in manufacturing and marketing of pharmaceutical products, bulk drugs, industrial chemicals, detergents, toiletries, electronics, engineering products, paper, glass and plastic containers and packaging materials.

Ambalal Sarabhai Ent Share Price

32.32 3.44 (11.91%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×